Position in PHAR
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$169,544
-$143,038 QoQ
Shares Held
10,189
-42.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PHAR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $5,780,974,653 across 374 Biotechnology names. PHAR ranks #310 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
2,182,571 | $356,894,009 | |
| 2 | ONC |
BeOne Medicines Ltd.
|
1,032,298 | $306,561,536 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
4,512,634 | $254,918,694 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,259,444 | $238,097,887 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
453,843 | $237,573,195 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
3,173,940 | $235,696,783 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
3,218,810 | $169,695,662 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
1,551,900 | $163,570,260 |
All Filings in PHAR
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $169,544 | 10,189 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $312,582 | 17,690 | Shares | Defined | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||